calcium acetate capsule
amneal pharmaceuticals llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). - patients with hypercalcemia. patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1) ] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. calcium acetate capsules contain calcium acetate and is excreted in human milk. human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored. safety and effectiveness in pediatric patients have not been established. clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other clinical experience has not identified differences in responses between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
calcium acetate capsule
zydus pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery
calcium acetate capsule
heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are
dbl leucovorin calcium folinic acid 15 mg/2ml (as calcium folinate) injection ampoule
pfizer australia pty ltd - calcium folinate, quantity: 16.2 mg (equivalent: folinic acid, qty 15 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections - leucovorin calcium has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions. leucovorin calcium has also shown good results in reducing the toxicity and circumventing the effect of folic acid antagonists, if therapeutically desired
calcium magnesium plus d tablet
nutrimetics international (canada) inc. - calcium (dolomite, egg, oyster shells); magnesium (dolomite, egg, oyster shells); vitamin d2 - tablet - 150mg; 85mg; 200unit - calcium (dolomite, egg, oyster shells) 150mg; magnesium (dolomite, egg, oyster shells) 85mg; vitamin d2 200unit - vitamins & minerals
calcium caps plus magnesium capsule
twin laboratories inc. - calcium (calcium carbonate); magnesium (magnesium oxide) - capsule - 300mg; 150mg - calcium (calcium carbonate) 300mg; magnesium (magnesium oxide) 150mg - minerals
calcium and mineral blend tab tablet
hillestad pharmaceuticals usa - calcium (oyster); calcium (egg shell); calcium (calcium lactate); calcium (calcium citrate); magnesium (magnesium hvp amino acid chelate); manganese (manganese hvp amino acid chelate); vitamin d3 - tablet - 80mg; 80mg; 20mg; 20mg; 80mg; 4mg; 80unit - calcium (oyster) 80mg; calcium (egg shell) 80mg; calcium (calcium lactate) 20mg; calcium (calcium citrate) 20mg; magnesium (magnesium hvp amino acid chelate) 80mg; manganese (manganese hvp amino acid chelate) 4mg; vitamin d3 80unit - vitamins & minerals
port a mins super cal-mag-zinc tablet
great earth companies, inc. - calcium (calcium succinate, calcium fumarate, calcium malate, oyster shells, calcium carbonate, calcium gluconate, calcium citrate, calcium hvp chelate); magnesium (magnesium oxide, magnesium hvp chelate, magnesium gluconate, magnesium ascorbate, magnesium citrate, magnesium succinate, magnesium fumarate, magnesium malate); zinc (zinc hvp chelate, zinc gluconate, zinc citrate, zinc succinate, zinc fumarate, zinc malate); vitamin d3 (cholecalciferol) - tablet - 500mg; 250mg; 25mg; 100unit - calcium (calcium succinate, calcium fumarate, calcium malate, oyster shells, calcium carbonate, calcium gluconate, calcium citrate, calcium hvp chelate) 500mg; magnesium (magnesium oxide, magnesium hvp chelate, magnesium gluconate, magnesium ascorbate, magnesium citrate, magnesium succinate, magnesium fumarate, magnesium malate) 250mg; zinc (zinc hvp chelate, zinc gluconate, zinc citrate, zinc succinate, zinc fumarate, zinc malate) 25mg; vitamin d3 (cholecalciferol) 100unit - vitamins & minerals
calcium acetate capsule
golden state medical supply, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate capsules, and there are no adequate and well controlled studies of calcium acetate capsules use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate capsules treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effec
calcium acetate capsule
nostrum laboratories, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate capsules, and there are no adequate and well controlled studies of calcium acetate capsules use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate capsules treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium a